FDA Approves Octapharma's Octagam 10% for Adult Dermatomyositis
Approvals, Clinical Trials, Dermatomyositis (DM), FDA, Immune Globulins, Intravenous Immunoglobulin (IVIg), R&D
The U.S. Food and Drug Administration granted approval to Octapharma USA for Octagam 10% [Immune Globulin Intravenous (Human)], the first intravenous immunoglobulin to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.
July 20, 2021 /by Andrew Humphreys
https://www.pharmalive.com/wp-content/uploads/2021/07/Octagam-10.jpg 465 402 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-07-20 11:35:362021-07-20 11:53:46FDA Approves Octapharma's Octagam 10% for Adult Dermatomyositis
U.S. FDA Approves Panzyga for Treatment of Adults with CIDP
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), FDA, Intravenous Immunoglobulin (IVIg), Peripheral Nerves, Pfizer, Rare Disorders, Supplemental Biologics License Application, Therapeutics
The U.S. Food and Drug Administration approved Pfizer Inc.'s supplemental Biologics License Application for Panzyga to treat adult patients with a rare neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy (CIDP).
February 12, 2021 /by Andrew Humphreys
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-02-12 17:10:432021-02-15 15:01:50U.S. FDA Approves Panzyga for Treatment of Adults with CIDP
Octapharma Uses IVIG as Potential Treatment for Covid-19
Antibodies, Blood, Business, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Coronavirus Infections, COVID-19 Deaths, Hospitalized COVID-19 Patients, Intravenous Immunoglobulin (IVIg), Plasma, R&D
Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill Covid-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as the company assesses the plasma-based treatment in a Phase III study.
https://www.pharmalive.com/wp-content/uploads/2020/08/Octapharma-Uses-IVIG-as-Potential-Treatment-for-COVID-19-BioSpace-8-7-20.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2020-08-08 01:00:562020-08-08 01:01:47Octapharma Uses IVIG as Potential Treatment for Covid-19
Some Studies Suggest IV Immunoglobulin Could Help Treat COVID-19
Blood Plasma, Coronavirus Disease 2019 (COVID-19), Immune Disorders, Intravenous Immunoglobulin (IVIg), Physicians, R&D, Researchers, Studies
As researchers and physicians try to identify ways to effectively treat and prevent COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, some are studying whether high-dose intravenous immunoglobulin (IVIg) could work. IVIg is a common blood plasma product that is used to treat other immune disorders.
May 4, 2020 /by Andrew Humphreys
https://www.pharmalive.com/wp-content/uploads/2020/05/Some-Studies-Suggest-IV-Immunoglobulin-Could-Help-Treat-COVID-19-BioSpace-5-4-20.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2020-05-04 11:20:422020-05-04 11:22:17Some Studies Suggest IV Immunoglobulin Could Help Treat COVID-19